Announcing a range of cost-cutting measures, the chief executive of Swiss biotech Idorsia has said it will take “longer than originally planned” for Quviviq (da 21 July 2023
Over the last few days, attendees of the ongoing annual meeting of the Alzheimer’s Association have been arriving in Amsterdam for what has turned out to be a p 18 July 2023
While targeted protein-busting antibodies are revolutionizing the treatment of Alzheimer’s disease, a damaging side effect - amyloid-related imaging abnormaliti 17 July 2023
At the AAIC in Amsterdam, we’re speaking with two key figures from Lilly's development program for donanemab, as the company presents new data that could help i 17 July 2023
In Alzheimer's, most of the focus has been on the newly-emerging class of intravenous biologics for early-stage disease, and the potential for subcutaneous vers 17 July 2023
Roche (SIX: ROG) has announced that the Phase III OCARINA II trial evaluating OCREVUS (ocrelizumab) as a twice-yearly 10-minute subcutaneous (SC) injection met 13 July 2023
The Journal of the American Medical Association (JAMA) has published key data on cytisinicline, from US specialty pharma Achieve Life Sciences. 12 July 2023
The recent full approval of Leqembi (lecanemab-irmb) has upped the stakes for what promises to be a particularly intriguing congress of the Alzheimer’s Associat 12 July 2023
US pharma major Bristol Myers Squibb Company has exercised its option to enter into an exclusive global licence agreement with German drug discovery company Evo 11 July 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.